Analyst Reco. Aprea Therapeutics, Inc.

Equities

APRE

US03836J2015

Market Closed - Nasdaq Other stock markets 16:30:00 2024-04-26 EDT			5-day change	1st Jan Change
5.2 ^USD	-2.80%		-2.80%	+10.64%

04-10	Aprea Therapeutics, Inc. Announces Presentations on Its Next Generation Wee1 Inhibitor, Apr-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, At AACR Annual Meeting 2024	CI
03-27	Wedbush Raises Aprea Therapeutics' PT to $11 From $9 After Layering In Recent Financing, Maintains Outperform Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush Raises Aprea Therapeutics' PT to $11 From $9 After Layering In Recent Financing, Maintains Outperform Rating	03-27	MT
Wedbush Raises Aprea Therapeutics' PT to $9 From $3, Says Keeps Outperform Rating; Continues to View Shares as 'Intriguingly Valued'	23-04-10	MT
Maxim Initiates Aprea Therapeutics at Buy Rating With $16 Price Target	23-03-10	MT
HC Wainwright Assumes Aprea Therapeutics at Buy with $3 Price Target	22-10-10	MT
Wedbush Initiates Aprea Therapeutics With Outperform Rating, $3 Price Target	22-07-07	MT
Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors	22-07-01	MT
Berenberg Bank Adjusts Aprea Therapeutics' Price Target to $1 From $4, Maintains Hold Rating	22-05-25	MT
HC Wainwright Adjusts Aprea Therapeutics' Price Target to $2 From $4, Maintains Neutral Rating	22-03-16	MT
RBC Trims Price Target on Aprea Therapeutics to $4 From $5, Maintains Sector Perform Rating, Speculative Risk Qualifier	22-03-16	MT
APREA THERAPEUTICS : JPMorgan Downgrades Aprea Therapeutics to Underweight From Neutral	21-08-20	MT
APREA THERAPEUTICS : HC Wainwright Adjusts Aprea Therapeutics' Price Target to $4 from $6, Keeps Neutral Rating	21-08-16	MT
APREA THERAPEUTICS : Berenberg Bank Downgrades Aprea Therapeutics to Hold From Buy Following Clinical Hold on Myeloid/Lymphoid Program, Adjusts PT to $4 From $10	21-08-16	MT
APREA THERAPEUTICS : RBC Cuts Price Target on Aprea Therapeutics to $5 From $6 Amid FDA Hold on Lymphoid Malignancy Trial; Sector Perform-Speculative Risk Rating Kept	21-08-13	MT
APREA THERAPEUTICS : Morgan Stanley Lowers Aprea Therapeutics to Underweight From Equal-Weight, Price Target to $3 From $5	21-08-13	MT
APREA THERAPEUTICS : RBC Reduces Price Target on Aprea Therapeutics to $6 From $7, Maintains Sector Perform, Speculative Risk	21-08-09	MT
DJ Industrial : Equities Little Changed in US Midday Trading as Markets Await Federal Reserve Rate Decision, Outlooks	21-06-16	MT
APREA THERAPEUTICS : RBC Cuts Price Target on Aprea Therapeutics to $7 From $8, Maintains Sector Perform, Speculative Risk	21-05-07	MT
APREA THERAPEUTICS : RBC Cuts Price Target on Aprea Therapeutics to $8 From $10, Maintains Sector Perform-Speculative Risk Rating	21-03-17	MT
APREA THERAPEUTICS : Morgan Stanley Adjusts Aprea Therapeutics' Price Target to $6 From $34, Keeps Equal-Weight Rating	20-12-29	MT
APREA THERAPEUTICS : HC Wainwright Adjusts Aprea Therapeutics' Price Target to $6 From $30, Maintains Neutral Rating	20-12-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Aprea Therapeutics, Inc.

Equities

APRE

US03836J2015

Analyst Reco.

Filters